The Clinical Value Of Proliferation Index Of Erythroid Progenitors In Megaloblastic Anemia And Myelodysplastic Syndrome

Objective:To investigate the the clinical value of proliferation index in erythroid progenitors as a new maker in the differential diagnosis in patients with megaloblastic anemia and myelodysplastic syndrome.Methods:Propidium iodide and immunofluorescent double staining through flow cytometry were applied to explore the cell cycle distributions in erythroid progenitors among patients with megaloblastic anemia and myelodysplastic syndrome and the control group, calculating the proliferation index of erythroid progenitors in each group. Results:1.Compared with the control group,the percentages of G0/G1phase of the cell cycle in erythroid progenitors were significantly decreased in the MA group(P<0.05),whereas the percentages of S and S+G2/M phase of the cell cycle in erythroid progenitors were both significantly increased(P<0.01);2.Compared with the control group,the percentages of G0/G1phase of the cell cycle in erythroid progenitors were significantly decreased in the MDS group,whereas the percentages of S and S+G2/M phase of the cell cycle in erythroid progenitors were both increased.But there were no significant differences among them(P>0.05).3.the percentages of G0/G1phase of the cell cycle in erythroid progenitors were significantly lower in the MA group compared the MDS group(P<0.05),accompanied by higher percentages of S and S+G2/M phase(.P<0.01).Conclusion:1.There has significant differences of the cell cycle distribution in erythroid progenitors between the patients with MA and MDS.2.Proliferation index can be a new maker in the differential diagnosis in the patients with MA and MDS.A significant higher proliferation index support the diagnosis of MA.